Cardiomyopathy and Worsened Ischemic Heart Failure in SM22-α Cre-Mediated Neuropilin-1 Null Mice: Dysregulation of PGC1α and Mitochondrial Homeostasis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 6, 2015, Pages 1401-1412

  Wang, Ying ^a   Cao, Ying ^a   Yamada, Satsuki ^b   Thirunavukkarasu, Mahesh ^e   Nin, Veronica ^c   Joshi, Mandip ^e,h   Rishi, Muhammed T ^e,h   Bhattacharya, Santanu ^a   Camacho Pereira, Juliana ^c   Sharma, Anil K ^d   Shameer, Khader ^a   Kocher, Jean Pierre A ^d   Sanchez, Juan A ^h   Wang, Enfeng ^a   Hoeppner, Luke H ^a   Dutta, Shamit K ^a   Leof, Edward B ^f   Shah, Vijay ^e   Claffey, Kevin P ^g   Chini, Eduardo N ^c   Simons, Michael ⁱ   Terzic, Andre ^b   Maulik, Nilanjana ^e   Mukhopadhyay, Debabrata ^a   more..

^a MAYO GRADUATE SCHOOL   (United States)

^b Divisions of Cardiovascular Diseases   (United States)

^c Division of Biomedical Statistics and Informatics   (United States)

^d Thoracic Diseases Research Unit   (United States)

^e MAYO CLINIC   (United States)

^f Molecular Cardiology and Angiogenesis Laboratory Department of Surgery   (United States)

^g UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^h ST MARY S HOSPITAL   (United States)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardiomyopathies; metabolomics; mitochondria; myocardial infarction; myocytes, cardiac; neuropilin 1

Indexed keywords

MITOCHONDRIAL DNA; NEUROPILIN 1; NOTCH1 RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SMAD2 PROTEIN; ACTIN BINDING PROTEIN; MUSCLE PROTEIN; PEROXISOME-PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA COACTIVATOR-1; TRANSCRIPTION FACTOR; TRANSGELIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIORESPIRATORY FITNESS; CONTROLLED STUDY; ENERGY EXPENDITURE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; ISCHEMIC CARDIOMYOPATHY; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL RATE; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CARDIAC MUSCLE CELL; CARDIOMYOPATHY; HEART MITOCHONDRION; HOMEOSTASIS; KNOCKOUT MOUSE; METABOLISM; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARDIOMYOPATHIES; HEART FAILURE; HOMEOSTASIS; MICE, KNOCKOUT; MICROFILAMENT PROTEINS; MITOCHONDRIA, HEART; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; NEUROPILIN-1; PPAR GAMMA; RECEPTOR CROSS-TALK; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSCRIPTION FACTORS;

EID: 84933041801     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.305566     Document Type: Article

References (60)

1. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, Mercurio AM. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 2001;61:5736-5740.
2. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin is a semaphorin III receptor. Cell. 1997;90:753-762.
3. Cao Y, Wang L, Nandy D, Zhang Y, Basu A, Radisky D, Mukhopadhyay D. Neuropilin-1 upholds dedifferentiation and propagation phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog axes. Cancer Res. 2008;68:8667-8672. doi: 10.1158/0008-5472.CAN-08-2614.
4. Banerjee S, Sengupta K, Dhar K, Mehta S, D'Amore PA, Dhar G, Banerjee SK. Breast cancer cells secreted platelet-derived growth factor-induced motility of vascular smooth muscle cells is mediated through neuropilin-1. Mol Carcinog. 2006;45:871-880. doi: 10.1002/mc.20248.
5. Glinka Y, Prud'homme GJ. Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity. J Leukoc Biol. 2008;84:302-310. doi: 10.1189/jlb.0208090.
6. Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, Yagi T, Fujisawa H. A requirement for neuropilin-1 in embryonic vessel formation. Development. 1999;126:4895-4902.
7. Kitsukawa T, Shimizu M, Sanbo M, Hirata T, Taniguchi M, Bekku Y, Yagi T, Fujisawa H. Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. Neuron. 1997;19:995-1005.
8. Levéen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev. 1994;8:1875-1887.
9. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, Cardell EL, Doetschman T. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development. 1997;124:2659-2670.
10. Behar O, Golden JA, Mashimo H, Schoen FJ, Fishman MC. Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature. 1996;383:525-528. doi: 10.1038/383525a0.
11. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92:735-745.
12. Lähteenvuo JE, Lähteenvuo MT, Kivelä A, Rosenlew C, Falkevall A, Klar J, Heikura T, Rissanen TT, Vähäkangas E, Korpisalo P, Enholm B, Carmeliet P, Alitalo K, Eriksson U, Ylä-Herttuala S. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1-and neuropilin receptor-1-dependent mechanisms. Circulation. 2009;119:845-856. doi: 10.1161/CIRCULATIONAHA.108.816454.. doi: 10.1161/CIRCULATIONAHA.108.816454.
13. Liu W, Parikh AA, Stoeltzing O, Fan F, McCarty MF, Wey J, Hicklin DJ, Ellis LM. Upregulation of neuropilin-1 by basic fibroblast growth factor enhances vascular smooth muscle cell migration in response to VEGF. Cytokine. 2005;32:206-212. doi: 10.1016/j.cyto.2005.09.009.
14. Gu C, Rodriguez ER, Reimert DV, Shu T, Fritzsch B, Richards LJ, Kolodkin AL, Ginty DD. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev Cell. 2003;5:45-57.
15. Lepore JJ, Cheng L, Min Lu M, Mericko PA, Morrisey EE, Parmacek MS. High-efficiency somatic mutagenesis in smooth muscle cells and cardiac myocytes in SM22alpha-Cre transgenic mice. Genesis. 2005;41:179-184. doi: 10.1002/gene.20112.
16. Frutkin AD, Shi H, Otsuka G, Levéen P, Karlsson S, Dichek DA. A critical developmental role for tgfbr2 in myogenic cell lineages is revealed in mice expressing SM22-Cre, not SMMHC-Cre. J Mol Cell Cardiol. 2006;41:724-731. doi: 10.1016/j.yjmcc.2006.06.067.
17. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 1999;98:115-124. doi: 10.1016/S0092-8674(00)80611-X.
18. Cao Y, Szabolcs A, Dutta SK, Yaqoob U, Jagavelu K, Wang L, Leof EB, Urrutia RA, Shah VH, Mukhopadhyay D. Neuropilin-1 mediates divergent R-Smad signaling and the myofibroblast phenotype. J Biol Chem. 2010;285:31840-31848. doi: 10.1074/jbc.M110.151696.
19. Bi P, Shan T, Liu W, Yue F, Yang X, Liang XR, Wang J, Li J, Carlesso N, Liu X, Kuang S. Inhibition of Notch signaling promotes browning of white adipose tissue and ameliorates obesity. Nat Med. 2014;20:911-918. doi: 10.1038/nm.3615.
20. Grueter CE, van Rooij E, Johnson BA, DeLeon SM, Sutherland LB, Qi X, Gautron L, Elmquist JK, Bassel-Duby R, Olson EN. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell. 2012;149:671-683. doi: 10.1016/j.cell.2012.03.029.
21. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A. 1997;94:4318-4323.
22. van Bilsen M, van Nieuwenhoven FA, van der Vusse GJ. Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc Res. 2009;81:420-428. doi: 10.1093/cvr/cvn282.
23. Rosca MG, Vazquez EJ, Kerner J, Parland W, Chandler MP, Stanley W, Sabbah HN, Hoppel CL. Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation. Cardiovasc Res. 2008;80:30-39. doi: 10.1093/cvr/cvn184.
24. Lim SY, Hausenloy DJ, Arjun S, Price AN, Davidson SM, Lythgoe MF, Yellon DM. Mitochondrial cyclophilin-D as a potential therapeutic target for post-myocardial infarction heart failure. J Cell Mol Med. 2011;15:2443-2451. doi: 10.1111/j.1582-4934.2010.01235.x.
25. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med. 2007;356:1140-1151. doi: 10.1056/NEJMra063052.
26. Chen L, Knowlton AA. Mitochondrial dynamics in heart failure. Congest Heart Fail. 2011;17:257-261.
27. Hagberg CE, Falkevall A, Wang X, et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature. 2010;464:917-921. doi: 10.1038/nature08945.
28. Hagberg CE, Mehlem A, Falkevall A, et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature. 2012;490:426-430. doi: 10.1038/nature11464.
29. Glinka Y, Stoilova S, Mohammed N, Prud'homme GJ. Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta. Carcinogenesis. 2011;32:613-621. doi: 10.1093/carcin/bgq281.
30. Gong K, Chen YF, Li P, Lucas JA, Hage FG, Yang Q, Nozell SE, Oparil S, Xing D. Transforming growth factor-? inhibits myocardial PPAR? expression in pressure overload-induced cardiac fibrosis and remodeling in mice. J Hypertens. 2011;29:1810-1819. doi: 10.1097/HJH.0b013e32834a4d03.
31. Fu M, Zhang J, Zhu X, Myles DE, Willson TM, Liu X, Chen YE. Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. J Biol Chem. 2001;276:45888-45894. doi: 10.1074/jbc.M105490200.
32. Han J, Hajjar DP, Tauras JM, Feng J, Gotto AM Jr, Nicholson AC. Transforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma. J Biol Chem. 2000;275:1241-1246.
33. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGFbeta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes. 2004;53:200-208.
34. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB; National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006;114:1883-1891. doi: 10.1161/CIRCULATIONAHA.106.632208.
35. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 2008;117:1717-1731. doi: 10.1161/CIRCULATIONAHA.107.653584.
36. Karatasakis GT, Karagounis LA, Kalyvas PA, Manginas A, Athanassopoulos GD, Aggelakas SA, Cokkinos DV. Prognostic significance of echocardiographically estimated right ventricular shortening in advanced heart failure. Am J Cardiol. 1998;82:329-334.
37. Di Salvo TG, Mathier M, Semigran MJ, Dec GW. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 1995;25:1143-1153.
38. Baker BJ, Wilen MM, Boyd CM, Dinh H, Franciosa JA. Relation of right ventricular ejection fraction to exercise capacity in chronic left ventricular failure. Am J Cardiol. 1984;54:596-599.
39. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:183-188.
40. Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc Natl Acad Sci U S A. 2006;103:10086-10091. doi: 10.1073/pnas.0603615103.
41. Leone TC, Lehman JJ, Finck BN, et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 2005;3:e101. doi: 10.1371/journal.pbio.0030101.
42. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest. 2000;106:847-856. doi: 10.1172/JCI10268.
43. Russell LK, Mansfield CM, Lehman JJ, Kovacs A, Courtois M, Saffitz JE, Medeiros DM, Valencik ML, McDonald JA, Kelly DP. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferatoractivated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stagedependent manner. Circ Res. 2004;94:525-533. doi: 10.1161/01. RES.0000117088.36577.E.B.
44. Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang LS, Goldberg IJ. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest. 2007;117:2791-2801. doi: 10.1172/JCI30335.
45. Tsioufis K, Andrikopoulos G, Manolis A. Trimetazidine and cardioprotection: facts and perspectives. Angiology. 2015;66:204-210. doi: 10.1177/0003319714530040.
46. Kantor PF, Dyck JR, Lopaschuk GD. Fatty acid oxidation in the reperfused ischemic heart. Am J Med Sci. 1999;318:3-14.
47. Palaniswamy C, Mellana WM, Selvaraj DR, Mohan D. Metabolic modulation: a new therapeutic target in treatment of heart failure. Am J Ther. 2011;18:e197-e201. doi: 10.1097/MJT.0b013e3181d70453.
48. Bristow M. Etomoxir: a new approach to treatment of chronic heart failure. Lancet. 2000;356:1621-1622. doi: 10.1016/S0140-6736(00)03149-4.
49. Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM. Cardiomyocyte-specific knockout and agonist of peroxisome proliferatoractivated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res. 2005;97:372-379. doi: 10.1161/01.RES.0000179226.34112.6d.
50. Lionetti V, Stanley WC, Recchia FA. Modulating fatty acid oxidation in heart failure. Cardiovasc Res. 2011;90:202-209. doi: 10.1093/cvr/cvr038.
51. Huss JM, Kelly DP. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest. 2005;115:547-555. doi: 10.1172/JCI24405.
52. Karamanlidis G, Nascimben L, Couper GS, Shekar PS, del Monte F, Tian R. Defective DNA replication impairs mitochondrial biogenesis in human failing hearts. Circ Res. 2010;106:1541-1548. doi: 10.1161/CIRCRESAHA.109.212753.
53. Ahuja P, Wanagat J, Wang Z, Wang Y, Liem DA, Ping P, Antoshechkin IA, Margulies KB, Maclellan WR. Divergent mitochondrial biogenesis responses in human cardiomyopathy. Circulation. 2013;127:1957-1967. doi: 10.1161/CIRCULATIONAHA.112.001219.
54. Zhou J, Pashmforoush M, Sucov HM. Endothelial neuropilin disruption in mice causes DiGeorge syndrome-like malformations via mechanisms distinct to those caused by loss of Tbx1. PLoS One. 2012;7:e32429. doi: 10.1371/journal.pone.0032429.
55. Goldmuntz E, Paluru P, Glessner J, Hakonarson H, Biegel JA, White PS, Gai X, Shaikh TH. Microdeletions and microduplications in patients with congenital heart disease and multiple congenital anomalies. Congenit Heart Dis. 2011;6:592-602. doi: 10.1111/j.1747-0803.2011.00582.x.
56. Cordell HJ, Töpf A, Mamasoula C, et al. Genome-wide association study identifies loci on 12q24 and 13q32 associated with tetralogy of Fallot. Hum Mol Genet. 2013;22:1473-1481. doi: 10.1093/hmg/dds552.
57. Turner ST, Bailey KR, Schwartz GL, Chapman AB, Chai HS, Boerwinkle E. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension. 2012;59:1204-1211. doi: 10.1161/HYP.0b013e31825b30f8.
58. Aslibekyan S, Kabagambe EK, Irvin MR, Straka RJ, Borecki IB, Tiwari HK, Tsai MY, Hopkins PN, Shen J, Lai CQ, Ordovas JM, Arnett DK. A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network. Pharmacogenet Genomics. 2012;22:191-197. doi: 10.1097/FPC.0b013e32834fdd41.
59. Comuzzie AG, Cole SA, Laston SL, Voruganti VS, Haack K, Gibbs RA, Butte NF. Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population. PLoS One. 2012;7:e51954. doi: 10.1371/journal.pone.0051954.
60. Gibson G. Rare and common variants: twenty arguments. Nat Rev Genet. 2011;13:135-145. doi: 10.1038/nrg3118.